Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8256073 | 0.86 | KDM4E (0.55) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL2722518 | 0.81 | BRD4 (0.60) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL1396628 | 0.79 | BRD4 (0.56) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL29706799 | 0.79 | BRD4 (0.61) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL3588753 | 0.79 | BRD4 (0.50) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL19030688 | 0.79 | BRD4 (0.61) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL755992 | 0.79 | BRD4 (0.50) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL18307135 | 0.79 | BRD4 (0.50) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL13574297 | 0.79 | BRD4 (0.50) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL754751 | 0.79 | PGR (0.42) | BRD4PGRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015124868-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | BRD4 120/4885PDE3B 2339/4885PDE3A 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.